Novavax (NasdaqGS:NVAX) recently amended its collaboration agreement with Takeda, enhancing its revenue potential through a new upfront payment structure and future royalties. These developments, ...

We expect Novavax NVAX to surpass expectations when it reports first-quarter 2025 earnings on May 8, before the opening bell.

Novavax Inc. closed 73.72% short of its 52-week high of $23.86, which the company achieved on June 6th.

In the most recent trading session, Novavax (NVAX) closed at $6.41, indicating no shift from the previous trading day.

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

Novavax (NASDAQ:NVAX) has updated the terms of the previously announced collaboration and licensing agreement with Takeda (TAK).

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might ...

Novavax (NVAX) closed the most recent trading day at $6.41, making no change from the previous trading session. This change lagged the S&P 500's 1.47% gain on the day. At the same time ...

Shares of Novavax Inc. NVAX slipped 3.90% to $6.41 Thursday, on what proved to be an all-around great trading session for the ...

Novavax’s (NVAX) stock is up after the FDA requested additional data for its COVID-19 vaccine. Unusual at first glance, the phrase “additional data” tends to inspire fear among biotechnology investors ...